With the $135.11/share all-cash acquisition by AbbVie pending close in Q3 2026, APGE shares are essentially locked near the deal price. The primary trading consideration is the merger arbitrage spread and any regulatory/special meeting timing updates. Watch for shareholder vote date and FTC review. The standalone pipeline milestones (Phase 3 AD, EoE, asthma) are now AbbVie's story.
Drugs in focus
APGE drug pipeline →zumilokibart
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2 complete (positive); Phase 3 planned/initiating 2H 2026
- Time to market
- Phase 3 initiation guided to 2H 2026 with a company-flagged potential 2029 commercial launch in atopic dermatitis — roughly 3 years from now, assuming Phase 3 success and a standard filing/PDUFA path.
- Next catalyst
- None dated
What to watchFor APGE holders, the drug's upside is essentially monetized, the stock trades ~0.7% below the $135.11 all-cash offer, so the remaining question is simply whether the AbbVie deal closes in Q3 2026 (mean analyst target $130.53 vs. price ~$134 reflects the capped upside). For AbbVie investors, zumilokibart is a 2030s thesis: watch Phase 3 initiation in atopic dermatitis (guided 2H 2026), interim data from the head-to-head versus Dupixent (2H 2026), and the ~$0.14 FY2026 EPS dilution the deal carries, the Phase 3 readouts that could validate the ~$10.9B price tag are years away.
Price Chart
Executive Summary
Apogee reported Q2 2026 financial results amid a transformational period: positive Phase 2 APEX Part B data for lead asset zumilokibart, a $1.3B non-dilutive financing collaboration with Blackstone Life Sciences, and the pending $10.9B acquisition by AbbVie at $135.11/share. Net loss widened to $85.9M from $66.1M YoY on higher R&D spend, but the acquisition agreement caps the stock near the deal price, rendering the earnings miss immaterial for current holders.
Key Facts
- AbbVie to acquire Apogee for $135.11 per share in cash, total equity value ~$10.9 billion.
- Blackstone Life Sciences provided up to $1.3B in non-dilutive capital to support zumilokibart Phase 3 and commercialization.
- Phase 2 APEX Part B met all primary/secondary endpoints: 65.9% EASI-75 (41.9% placebo adjusted), supporting mid-dose for Phase 3 initiation in 2H 2026.
- Expansion trials announced: ELEVATE Phase 2a in EoE (2H 2026) and ASPIRE Phase 2b registrational asthma trial (1H 2027).
- Cash position $1.3B as of June 30, 2026, extending runway into 2029.
- Q2 2026 net loss of $85.9M vs $66.1M YoY; R&D expenses $67.3M vs $55.7M YoY.
- Revenue share liability of ~$99.2M recorded related to the Blackstone financing.
- Transaction expected to close in Q3 2026, subject to shareholder and regulatory approvals.
Financial Impact
Acquisition valued at ~$10.9B total equity; Blackstone financing up to $1.3B non-dilutive capital; net loss of $85.9M in Q2 2026.
Risk Factors
- Transaction may fail to close due to regulatory hurdles or failure to obtain shareholder approval; break fee and litigation risk exist.
- Zumilokibart Phase 3 results may not replicate Phase 2 efficacy; pipeline-expansion data (EoE, asthma) face clinical risk under AbbVie.
- Expenses continuing to increase without revenue; business reliant on financing and acquisition proceeds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-341239 |
| Document: apge-20260810.htm | 0001193125-26-341239 |
| Document: 0001193125-26-341239-index-headers.html | 0001193125-26-341239 |
| Document: 0001193125-26-341239-index.html | 0001193125-26-341239 |
| Document: 0001193125-26-341239.txt | 0001193125-26-341239 |
| 8-K Data (Synthetic) | 0001193125-26-341239 |
Track record
31 reports on APGE
9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 Viewing No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers